Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Covidien buys Power Medical Interventions

This article was originally published in The Gray Sheet

Executive Summary

Firm will acquire Power Medical Interventions, maker of computer-assisted surgical cutting and stapling products, for about $64 million including debt, in an all-cash tender offer. The Langhorne, Pa.-based firm had 2008 revenues of $9 million. PMI's products include the SurgAssist power stapler and wireless Intelligent Surgical Instruments, such as the firm's i60 articulating endoscopic linear cutter for laparoscopic surgery. PMI also has standing agreements with Intuitive Surgical to jointly develop a novel surgical stapling device that will attach to Intuitive's da Vinci surgical system. Covidien said in a July 30 third-quarter earnings call it will honor those agreements and "look[s] forward to working with Intuitive." PMI's stock price rose 250% from $0.58 to $2.03 following the July 29 announcement. The deal is expected to close by Sept. 25. A Covidien subsidiary will pay $2.08 per share for PMI's common stock

You may also be interested in...

Covidien Gains BIS Anesthesia Monitoring Technology In Aspect Medical Buy

Covidien is adding brain monitoring technology to its lineup through the $210 million acquisition of Aspect Medical Systems, announced Sept. 28

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts